The global clinical trials activity saw a decrease of 12.2% in Q3 2022, when compared with the rolling average of the last four quarters (Q3 2021 to Q2 2022), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 51.8% share in Q3 2022, marking an increase of 1.2% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 48.2% share of all the clinical trials globally in Q2 2022, marking a decrease of 1.2% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q3 2022
Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2022, accounting for a 28.9% share of all trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis was followed by the following therapy areas: Central Nervous System with a 13.9% share, Infectious Disease with a 13.6% share, Metabolic Disorders with an 8.5% share and Gastrointestinal with a 6.7% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.3% share, followed by Infectious Disease with a 15.7% share, Central Nervous System with a 14.6% share, Metabolic Disorders with an 8.3% share, and Cardiovascular with an 8.2% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2022 | Activity |
| Oncology | 27.3% | 28.9% |  |
| Central Nervous System | 14.6% | 13.9% |  |
| Infectious Disease | 15.7% | 13.6% | |
| Metabolic Disorders | 8.3% | 8.5% | |
| Gastrointestinal | 7.0% | 6.7% | |
| Cardiovascular | 8.2% | 6.6% | |
| Dermatology | 5.0% | 5.5% | |
| Respiratory | 5.9% | 4.9% | |
| Immunology | 5.6% | 4.4% | |
| Musculoskeletal Disorders | 4.1% | 3.8% | |
| Hematological Disorders | 2.9% | 3.1% | |
| Ophthalmology | 2.9% | 3.0% | |
| Women’s Health | 1.9% | 2.4% | |
| Genito Urinary System And Sex Hormones | 2.8% | 2.3% | |
| Genetic Disorders | 1.8% | 1.9% | |
| Ear Nose Throat Disorders | 1.7% | 1.2% | |
| Male Health | 1.0% | 0.6% | |
| Mouth and Dental Disorders | 0.5% | 0.6% | |
| Hormonal Disorders | 0.8% | 0.5% | |
| Non Malignant Disorders | 0.3% | 0.4% | |
| Nutritional Disorders | 0.3% | 0.2% | |
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q3 2022, accounting for a 26.2% share of all trials.
This was followed by the following therapy areas: Oncology with a 25.8% share, Cardiovascular with a 9.7% share, Infectious Disease with a 9.5% share, and Gastrointestinal with a 6.5% share.
In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 25.5%, followed by Oncology with a 23.4% share, Infectious Disease with a 12.5% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.4% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2022 | Activity |
| Central Nervous System | 25.5% | 26.2% | |
| Oncology | 23.4% | 25.8% | |
| Cardiovascular | 8.9% | 9.7% | |
| Infectious Disease | 12.5% | 9.5% | |
| Gastrointestinal | 6.4% | 6.5% | |
| Metabolic Disorders | 5.4% | 6.5% | |
| Musculoskeletal Disorders | 5.3% | 5.4% | |
| Dermatology | 2.6% | 3.7% | |
| Respiratory | 4.0% | 3.7% | |
| Women’s Health | 4.5% | 3.6% | |
| Genito Urinary System And Sex Hormones | 2.8% | 3.4% | |
| Hematological Disorders | 3.0% | 2.9% | |
| Immunology | 3.0% | 2.9% | |
| Mouth and Dental Disorders | 2.6% | 2.9% | |
| Ophthalmology | 2.0% | 2.2% | |
| Genetic Disorders | 0.6% | 1.3% | |
| Ear Nose Throat Disorders | 1.1% | 0.8% | |
| Nutritional Disorders | 0.7% | 0.8% | |
| Hormonal Disorders | 0.8% | 0.7% | |
| Male Health | 0.7% | 0.6% | |
| Non Malignant Disorders | 0.3% | 0.4% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q3 2022
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q3 2022 with a 54.3% share, compared to 57.0% in the last four quarters.
North America stood at second place with a 32.3% share in Q3 2022, over 28.5% in the last four quarters, followed by Europe with a 25.6% share in Q3 2022, as against 26.5% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.6% share in industry sponsored clinical trials in Q3 2022 when compared with 86.0% of average recorded in the last four quarters. Multinational trials accounted for a 14.4% share in Q3 2022, as against the four-quarter average of 14.1%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q3 2022 with a 58.9% share, over 55.3% in the last four quarters.
North America held the second position with a 22.5% share in Q3 2022, over 15.5% in the last four quarters, followed by Europe with a 13.3% share in Q3 2022, as against 13.4% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.8% share for non-industry sponsored clinical trials in Q3 2022, compared to 99.0% in the last four quarters. Multinational trials accounted for a 1.2% share in Q3 2022, as against 1.0% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q3 2022
Phase I trials outnumbered all other studies with a 36.2% share for industry sponsored trials in Q3 2022, compared to 40.1% average in the last four quarters.
The share of Phase II trials stood at 35.8% in Q3 2022, as against the four-quarter average of 33.5%. Phase III trials held a 17.1% share in Q3 2022, registering an increase of 1.8% over the last four quarters average, followed by Phase IV trials with an 11.0% share in Q3 2022, as against the four-quarter average of 11.1%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 50.7% share for non-industry sponsored clinical trials in Q3 2022, compared to 44.0% in the last four quarters.
Phase IV trials stood at second place with a 20.6% share in Q3 2022, compared to 22.6% in the last four quarters. Phase I trials held a 17.7% share in Q3 2022, as against 17.1% in the last four quarters, followed by Phase III trials with an 11.1% share in Q3 2022 over 16.4% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
